汪伟于2013年6月本科毕业于湘南学院应用化学专业，2016年7月硕士毕业于湘潭大学化学工程与技术专业，2016.06-2019.08分别在东莞东阳光科技集团和中山大学药学院分别从事有机合成研究员和研究助理工作。于2019年9月进入中山大学药学院(深圳)高理钱老师课题组开始研究生期间的学习，现为中山大学2019级在读博士研究生。2021年9月，获得国家留学基金委CSC奖学金公派新加坡国立大学YAO Shao Q.教授课题组进行联合培养博士学习。

E-mail: wangw286@mail2.sysu.edu.cn

Publications (After joining SYSU) （# Equal contribution, * Corresponding author）

1. B. Sharma#, L. Xie#, F. Yang#, W. Wang#, Q. Zhou, M. Xiang, S. Zhou, W. Lv, Y. Jia, L. Pokhrel, J. Shen, Q. Xiao*, L. Gao*, W. Deng*, “Recent advance on PTP1B inhibitors and their biomedical applications”, European Journal of Medicinal Chemistry (2020), 199:112376, doi:10.1016/j.ejmech.2020.112376.

2. L. Gao*,#, W. Wang#, X. Wang#, F. Yang, L. Xie, J. Shen, M.A. Brimble, Q. Xiao*, S. Q. Yao*, “Fluorescent probes for bioimaging of potential biomarkers in  Parkinson’s disease”, Chem Soc Rev (2021), 50(2), 1219-1250.

3. M. Xiang#, Q. Zhou#, Z. Shi, X. Wang, M. Li, Y. Jia, S. Li, F. Yang, W. Wang, T. Chen, X. Xu, B. Sharma, Y. Nie, Q. Xiao*, L. Gao*, “A review of light sources and enhanced targeting for photodynamic therapy”, Current Medicinal Chemistry (2021), 28(31), 6437-6457. 

4. W.J. Shi*, L., Feng, X. Wang, Y. Huang, Y.F. Wei, Y.Y. Huang, H.J. Ma, W. Wang, M.H. Xiang, L. Gao*, “A near-infrared-emission aza-BODIPY-based fluorescent probe for fast, selective, and “turn-on” detection of HClO/ClO^-”, Talanta (2021), 233,122581.

5. F. Yang#, D. Zhang#, Q. Zhou#, M. Li, C. Xie, S. Li, X. Wang, W. Wang, Y. Guo, Q. Xiao*, Y. Wang *, L. Gao*, “Peptides-modified polystyrene-based polymers as high-performance substrates for the growth and propagation of human embryonic stem cells”, Chinese Chemical Letters (2021), DOI:10.1016/j.cclet.2021.10.028.

6. J. Qin*, W. Wang, L. Gao, S.Q. Yao*, “Emerging Biosensing and Transducing Techniques for Potential Applications in Point-of-Care Diagnostics”, Chemical Science (2021), 13, 2857-2876.

7. P. Chen#, J. Sun#, C. Zhu#, G. Tang*, W. Wang, M. Xu, M. Xiang, C.-J. Zhang, Z.-M. Zhang*, L. Gao*, S. Q. Yao*, “Cell-active, reversible and irreversible covalent inhibitors that selectively target the catalytic lysine of BCR-ABL kinase”, Angew. Chem. Int. Ed. (2022), 61(26):e202203878.

8.P. Chen#, G. Tang#, *, C. Zhu#, J. Sun, X. Wang, M. Xiang, H. Huang, W. Wang, L. Li, Z. Zhang*, L. Gao*, S.Q. Yao*, “ 2-Ethynylbenzaldehyde (EBA)-based, lysine-targeting irreversible covalent inhibitors for protein kinases and non-kinases”, J. Am Chem. Soc. (2023), 145 (7)，3844-3849, 中科院1区，Top Journal).

9.  L. Lou#, S. Zhou#, S. Tan#, M. Xiang, W. Wang, C. Yuan*, L. Gao* and Q. Xiao*, “Amplifying the Efficacy of ALA-based Prodrugs for Photodynamic Therapy Using Nanotechnology”, Frontiers in Pharmacology (2023), in press.

Patents

1. 高理钱，谢刘幸，李孟础，王璇，汪伟，肖奇才，杨芬，沈君，邓文斌。 “靶向GRB2 SH2结合域的抗肿瘤多肽及其应用”, 中国发明专利申请号：CN201911258905.8, 申请日 2019年12月10日

2. 肖奇才，高理钱，周全明，石子寒，汪伟，向梦华，谢刘幸，杨芬，罗川朝。“一种氟替卡松丙酸酯中间体的制备方法”。中国发明专利申请号：CN202010150457.6, 申请日2020年03月06日